Analysts See $-1.31 EPS for Five Prime Therapeutics, Inc. (FPRX); Shorts at Amerisafe (AMSF) Lowered By 7.82%

Analysts expect Five Prime Therapeutics, Inc. (NASDAQ:FPRX) to report $-1.31 EPS on February, 26.They anticipate $0.27 EPS change or 25.96% from last quarter’s $-1.04 EPS. After having $-1.37 EPS previously, Five Prime Therapeutics, Inc.’s analysts see -4.38% EPS growth. The stock increased 0.96% or $0.11 during the last trading session, reaching $11.62. About 243,469 shares traded. Five Prime Therapeutics, Inc. (NASDAQ:FPRX) has declined 47.75% since February 14, 2018 and is downtrending. It has underperformed by 47.75% the S&P500. Some Historical FPRX News: 30/05/2018 – FIVE PRIME PACT TO DEVELOP IHC COMPANION DIAGNOSTIC ASSAY; 08/05/2018 – FIVE PRIME THERAPEUTICS INC – ESTIMATES ENDING 2018 WITH APPROXIMATELY $250 MLN IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES; 30/05/2018 – Five Prime Therapeutics Announces Collaboration with Roche to Develop Companion Diagnostics for Targeted Immuno-Oncology; 03/04/2018 – Personal Genome Diagnostics Announces Collaboration to Develop Plasma-Based Companion Diagnostic for Five Prime Therapeutics’ T; 04/05/2018 – Five Prime Presenting at Conference Jun 3; 30/05/2018 – Five Prime Therapeutics Announces Collaboration With Roche to Develop Companion Diagnostics for Targeted Immuno-Oncology Investigational Drug Candidates; 10/04/2018 – FIVE PRIME THERAPEUTICS – TO CLOSE BLADDER CANCER COHORT OF PHASE 1 TRIAL EVALUATING BEMARITUZUMAB TREATING PATIENTS WHOSE TUMORS OVEREXPRESS FGFR2B PROTEIN; 03/04/2018 – PERSONAL GENOME, FIVE PRIME IN PACT FOR DIAGNOSTIC ASSAY; 30/05/2018 – FIVE PRIME SAYS FINL TERMS OF PACT NOT DISCLOSED; 14/05/2018 – Great Point Partners Buys New 2.5% Position in Five Prime

Amerisafe Inc (NASDAQ:AMSF) had a decrease of 7.82% in short interest. AMSF’s SI was 812,800 shares in February as released by FINRA. Its down 7.82% from 881,800 shares previously. With 78,100 avg volume, 10 days are for Amerisafe Inc (NASDAQ:AMSF)’s short sellers to cover AMSF’s short positions. The SI to Amerisafe Inc’s float is 4.31%. The stock increased 1.56% or $0.97 during the last trading session, reaching $63.25. About 70,075 shares traded. Amerisafe, Inc. (NASDAQ:AMSF) has risen 0.36% since February 14, 2018 and is uptrending. It has outperformed by 0.36% the S&P500. Some Historical AMSF News: 23/04/2018 – Amerisafe at Burkenroad Reports Investment Conference Apr 27; 25/04/2018 – AMERISAFE INC QTRLY DILUTED EARNINGS PER SHARE $ 0.84; 25/04/2018 – AMERISAFE 1Q OPER EPS 86C, EST. 77C; 26/04/2018 – Amerisafe Closes Above 200-Day Moving Average: Technicals; 25/04/2018 – AMERISAFE INC QTRLY OPERATING EARNINGS PER SHARE $ 0.86; 25/04/2018 – AMERISAFE INC QTRLY NET PREMIUMS EARNED $ 87.3 MLN VS $ 90.9 MLN; 25/04/2018 – AMERISAFE 1Q EPS 84c; 26/04/2018 – Amerisafe at Burkenroad Reports Investment Conference Tomorrow; 24/05/2018 – A.M. Best Upgrades Issuer Credit Ratings of AMERISAFE, Inc. and Its Operating Subsidiaries; 19/03/2018 AMERISAFE Announces Date of Annual Meeting of Shareholders and Record Date

Among 3 analysts covering Five Prime Therapeutics (NASDAQ:FPRX), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Five Prime Therapeutics had 3 analyst reports since August 20, 2018 according to SRatingsIntel. The firm has “Outperform” rating by Leerink Swann given on Thursday, September 13. The firm earned “Buy” rating on Monday, August 20 by Citigroup. The firm earned “Outperform” rating on Thursday, January 17 by Wedbush.

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics in the United States. The company has market cap of $412.11 million. The company's product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor and is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor, as well as conducts Phase I clinical trials for the treatment of rheumatoid arthritis. It currently has negative earnings. The Company’s product candidates also comprise FPA144, an antibody that inhibits fibroblast growth factor receptor IIb and is in Phase I clinical trials to treat patients with gastric cancer; and FP-1039, a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors.

Investors sentiment increased to 1.15 in 2018 Q3. Its up 0.05, from 1.1 in 2018Q2. It increased, as 20 investors sold Five Prime Therapeutics, Inc. shares while 27 reduced holdings. 19 funds opened positions while 35 raised stakes. 30.25 million shares or 0.19% less from 30.31 million shares in 2018Q2 were reported. Great Point Prtnrs Ltd has 1.65 million shares. Walleye Trading Lc stated it has 17,627 shares or 0% of all its holdings. Jefferies Limited Liability has invested 0% in Five Prime Therapeutics, Inc. (NASDAQ:FPRX). Millennium Mngmt Ltd Limited Liability Company reported 142,721 shares or 0% of all its holdings. Citigroup stated it has 0% of its portfolio in Five Prime Therapeutics, Inc. (NASDAQ:FPRX). Ancora Advsr Limited Liability Com owns 10,000 shares for 0.01% of their portfolio. 2.91M are owned by Blackrock. Geode Management Ltd Co has 0% invested in Five Prime Therapeutics, Inc. (NASDAQ:FPRX). Pub Employees Retirement Association Of Colorado stated it has 7,002 shares or 0% of all its holdings. 11,290 are held by Ameriprise Fincl. Barclays Public Ltd Com reported 0% stake. Dekabank Deutsche Girozentrale owns 284,200 shares. Fifth Third National Bank stated it has 0% of its portfolio in Five Prime Therapeutics, Inc. (NASDAQ:FPRX). California State Teachers Retirement System holds 0% of its portfolio in Five Prime Therapeutics, Inc. (NASDAQ:FPRX) for 51,023 shares. Proshare Limited Liability Corporation reported 0% of its portfolio in Five Prime Therapeutics, Inc. (NASDAQ:FPRX).

More notable recent Five Prime Therapeutics, Inc. (NASDAQ:FPRX) news were published by: Nasdaq.com which released: “Consolidated Research: 2019 Summary Expectations for Southern, Exelon, PriceSmart, Five Prime Therapeutics, Digi International, and Voyager Therapeutics — Fundamental Analysis, Key Performance Indications – Nasdaq” on January 16, 2019, also Nasdaq.com with their article: “Five Prime Therapeutics, Inc. (FPRX) Shares March Higher, Can It Continue? – Nasdaq” published on January 24, 2019, Seekingalpha.com published: “Five Prime to cut 41 jobs in restructuring – Seeking Alpha” on January 15, 2019. More interesting news about Five Prime Therapeutics, Inc. (NASDAQ:FPRX) were released by: Seekingalpha.com and their article: “Goldman bullish on Insmed in premarket analyst action – Seeking Alpha” published on January 17, 2019 as well as Businesswire.com‘s news article titled: “Five Prime Therapeutics Presents Data from Safety Lead-in to Phase 3 FIGHT Trial of Bemarituzumab at 2019 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium – Business Wire” with publication date: January 17, 2019.

More notable recent Amerisafe, Inc. (NASDAQ:AMSF) news were published by: Nasdaq.com which released: “Amerisafe Breaks Above 200-Day Moving Average – Bullish for AMSF – Nasdaq” on February 11, 2019, also Nasdaq.com with their article: “Factors of Influence in 2019, Key Indicators and Opportunity within Park Hotels & Resorts, Planet Fitness, Aevi Genomic Medicine, Ardelyx, AMERISAFE, and inTest — New Research Emphasizes Economic Growth – Nasdaq” published on February 12, 2019, Nasdaq.com published: “AMERISAFE Announces 2018 Fourth Quarter and Full Year Earnings Release and Conference Call Schedule – Nasdaq” on January 16, 2019. More interesting news about Amerisafe, Inc. (NASDAQ:AMSF) were released by: Globenewswire.com and their article: “AMERISAFE Announces 2018 Third Quarter Results Nasdaq:AMSF – GlobeNewswire” published on October 24, 2018 as well as Nasdaq.com‘s news article titled: “Noteworthy Thursday Option Activity: TTWO, MU, AMSF – Nasdaq” with publication date: December 13, 2018.

AMERISAFE, Inc., an insurance holding company, provides workersÂ’ compensation insurance in the United States. The company has market cap of $1.22 billion. The Company’s workersÂ’ compensation insurance policies provide benefits to injured employees for temporary or permanent disability, death, and medical and hospital expenses. It has a 22.83 P/E ratio. The firm serves small to mid-sized employers involved in construction, trucking, logging and lumber, manufacturing, agriculture, maritime, gas and oil, and other industries through agencies.

Investors sentiment decreased to 1.12 in 2018 Q3. Its down 0.46, from 1.58 in 2018Q2. It turned negative, as 6 investors sold Amerisafe, Inc. shares while 53 reduced holdings. 20 funds opened positions while 46 raised stakes. 18.96 million shares or 15.93% less from 22.56 million shares in 2018Q2 were reported. Employees Retirement Association Of Colorado stated it has 0.11% in Amerisafe, Inc. (NASDAQ:AMSF). Zurcher Kantonalbank (Zurich Cantonalbank) stated it has 891 shares or 0% of all its holdings. S&T Bank & Trust Pa invested in 158,572 shares or 1.83% of the stock. 587 are owned by Ls Invest Advsrs Limited Liability Corp. Engineers Gate Manager Lp invested 0.02% in Amerisafe, Inc. (NASDAQ:AMSF). Regions Corp reported 0% in Amerisafe, Inc. (NASDAQ:AMSF). Schroder Inv Management Group Inc stated it has 0.04% of its portfolio in Amerisafe, Inc. (NASDAQ:AMSF). Victory Management Inc, Ohio-based fund reported 1.13M shares. Voya Mgmt Limited Liability accumulated 454,013 shares. Walthausen And Ltd Llc holds 106,130 shares or 0.63% of its portfolio. Stone Ridge Asset Management Limited Liability Co owns 0.05% invested in Amerisafe, Inc. (NASDAQ:AMSF) for 14,208 shares. Segall Bryant & Hamill owns 13,081 shares or 0.01% of their US portfolio. Wells Fargo And Mn, a California-based fund reported 44,537 shares. Menta Cap Ltd holds 10,418 shares. Tower Capital Ltd Com (Trc) invested in 378 shares.

Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Institutional Positions Chart